onc brain

Biomarker analyses (Decipher, PAM50) drawn from the postoperative trials NRG/RTOG 9601 and 0534. Analysis design, N and endpoints not stated in source.

Source gives no effect sizes, cohort sizes or endpoints for the biomarker analyses; the image content was not accessible.

Design not stated in source; described as a real-world benchmark. Median follow-up 60 mo.

Reported: 5-yr BCR-FS, 5-yr MFS, 5-yr CSS. No primary endpoint or effect size stated.

Framed as a reference point for perioperative treatment strategies in high-risk disease, not a test of one. Useful only once the cohort definition and treatments received are known, since those determine which trial populations it can benchmark.

Descriptive benchmark with no comparator, N, eligibility, or treatment details in source; cannot classify impact on any perioperative decision.

A point-counterpoint conference presentation, arguing the negative position. The evidence marshalled is three published studies: a prospective single-arm imaging trial (n=16 evaluable), a bipolar androgen therapy series (n=6), and the RECIP 1.0 framework paper.

The anchor trial enrolled pts with APMR starting abiraterone or enzalutamide, imaged with 18F-DCFPyL PET/CT immediately before therapy and again at 2-4 months. The BAT series imaged at baseline and 3 months.

Prognostic separation was consistent across both quantitative stratifiers, with DPSM HR 5.03 (95% CI 1.17-21.65) and DASM HR 9.31 (95% CI 1.81-47.87) for overall survival. A mixed but predominantly increased uptake pattern marked the shorter time to therapy change.

RECIP 1.0 is the field's standardization attempt, categorizing PD/PR/SD/CR by combining PSMA PET with CT, but it was derived in the radioligand therapy setting and its transfer to AR-directed therapy is exactly what Rowe argues is unestablished.

Beyond the small samples, the measurement layer itself is unvalidated: repeatability work using Bland-Altman, ICC, and within-subject coefficient of variation found lesion identification and segmentation variability material even above 1.5 cm³. A biomarker whose test-retest behaviour is uncertain cannot support a serial-change decision rule.

The talk separates two claims that often get merged: that post-therapy PSMA PET change is prognostic, which the data support, and that it is a valid response assessment, which requires reproducibility and a therapy-independent relationship between uptake and burden. Prognostic value in a 16-patient series does not license per-patient treatment decisions.

Conference position talk, not a result. Its supporting datasets are n=16 and n=6 prospective series; no comparative design establishes or refutes PET response assessment.

Prospective statewide quality-consortium data (MROQC), N=553 across 26 centers, June 2020 to November 2024. Multivariable analysis of predictors, a mixed-effects model with treatment site as random intercept, and ARPI adoption compared before vs after STAMPEDE M0 publication.

Intact high-risk M0, N0-1 prostate cancer treated with definitive RT: cT3/4 13.3%, cN1 19.9%, GG 4-5 75.0%, PSA ≥20 ng/mL 40.0%. 27.9% met STAMPEDE M0 criteria (≥2 of cT3/T4, GG 4-5, PSA ≥40 ng/mL, or cN1).

Primary: intended guideline-concordant ADT (GC-ADT, ≥18 months) per 2022 AUA/ASTRO. Also assessed: ARPI recommendation in STAMPEDE-eligible pts and facility-level variability.

91.3% recommended any ADT, 67.0% guideline-concordant. ARPI recommendations in STAMPEDE-eligible pts rose from 0% to 23.2% after publication; facility variability persisted on MVA (P<.0001).

Benchmarks practice against the 2022 AUA/ASTRO 18-36 month recommendation and STAMPEDE M0 ARPI intensification criteria. Single-state data, and the source offers no comparison with other practice settings.

The abstract gives no reasons for sub-18mo recommendations (comorbidity, pt preference, toxicity), so non-concordance is not necessarily poor care. The ARPI comparison is an uncontrolled before-after design, and no OR is reported for cT3/4.

The strongest predictors of a concordant recommendation were grade group (GG5 OR 9.45) and cN1, consistent with shorter courses being offered when high-risk status rests on other features. Residual site variability points to local norms beyond the modelled case mix, though unmeasured covariates could contribute.

Practice-patterns study of intended ADT recommendations; no efficacy or outcome endpoint, so nothing here confirms or challenges SOC.

Design not stated in source. Commentary frames the comparison as an ADT + apalutamide arm vs ADT alone; results published in NEJM alongside ASCO 2026.

Source names EFS and MFS. Primary endpoint and its effect size are not reported in source tweets.

Most distant metastases were identified by PSMA PET: 53.0% of those in the apalutamide group and 60.7% in the second group (label truncated in source).

The BCR counts (60 vs 50 per 100) come from a hypothetical thought experiment, not trial data. The arm attribution of the 60.7% figure is truncated in the source tweet.

A PET-dominated MFS event mix means the endpoint is not interchangeable with conventional-imaging MFS. Whether the result is a benefit or a negative trial, as the commentator frames the debate, cannot be settled from the source.

Source tweets give no primary endpoint result, design, phase or population; only the imaging mode of distant-met detection is stated.

Not reported in source. The tweet gives a 5-year local control figure with no study type, N, institution, or registry identifier, so design cannot be inferred.

SBRT to primary RCC; dose, fractionation, number of fractions, and target definition are not reported in source. These are the parameters that gate transfer to practice, and none are available here.

100% local control at 5 years as stated in the source tweet. No confidence interval, no n-at-risk, and no statement of whether this is a Kaplan-Meier estimate or a crude proportion.

Beyond the missing design, the specific risk is effective follow-up: a medically inoperable RCC cohort loses pts to non-cancer death well before 5y, so a 100% figure can rest on very few pts at risk. Local control definition (RECIST-style size change vs absence of growth vs biopsy) is also unstated and swings the estimate.

Single tweet with one number, no N, design, dose, or LC definition. Cannot judge whether the 100% figure reflects efficacy or short effective follow-up.

Two de-escalation levers reported in source: contralateral neck sparing in a specified subgroup, and reduction of the primary CTV dose to 56 Gy. Fractionation, technique, and the dose to involved or high-risk volumes are not stated in the source text.

Described as a trial, but phase, randomisation, N, sites, and follow-up are not stated in the source tweet.

No primary endpoint, effect size, or toxicity result reported in source. The tweet is commentary on the trial's approach, not its results.

Everything that would let a reader act on this is missing from the source: the selection rule for contralateral neck omission, the comparator, and any locoregional control or late-toxicity figures. A de-escalation result is only interpretable against its non-inferiority margin, which is not given.

Source is a single commentary tweet with no design, N, endpoint, or effect size. Nothing to classify beyond the de-escalation concept.